Ge Long Hui·2025-08-19 05:57Core Viewpoint - Bank of America Securities reports that JD Health's revenue for the first half of the year increased by 25% year-on-year to 35.3 billion yuan, and adjusted net profit rose by 35% to 3.6 billion yuan, both exceeding expectations [1] Financial Performance - Adjusted operating profit increased by 61% year-on-year [1] - The company has raised its adjusted operating profit forecasts for 2025 to 2027 by 13% to 14% [1] Growth Drivers - Two main factors driving the strong performance in the first half are the increase in offline pharmacy market share and the rise in advertising budgets for healthcare brands [1] Target Price and Ratings - The target price for JD Health has been raised from 50 HKD to 68 HKD, maintaining a "Buy" rating [1] - The company is expected to achieve revenue and adjusted operating profit growth of 15% and 26% respectively in 2026, surpassing Alibaba Health's projected growth of 10% and 22% [1]